AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... molecule is as sneaky as its inventors ... COPD and BPD: Inhalation of Live Lactobacilli Lessens Lung Inflammation and Improves ...

New MRI lung scanning method could change treatment for compromised lung function in transplant patients. Read on!

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

When patients cannot adhere to inhaler instructions — whether because of cognitive or physical limitations — a nebulized LAMA might offer another method to safely deliver medication. To that end, GOLD ...

New Disney Plus movies are set to be a common occurrence in 2025. With Disney set to release a whole host of new movies in theaters and on its primary streaming platform, there'll be plenty for ...